SAN MARINO, Calif.--(BUSINESS WIRE)--Viral Genetics (Pinksheets: VRAL) today published its April 2012 Letter to Shareholders. Providing updates on the company’s progress, the letter discusses the expanded product development pipeline for the Targeted Peptide and the Metabolic Disruption Technology platforms, as well as developments at the VG Energy subsidiary, and moves being made to manage this new growth.
